NBT Bank N.A. Makes New Investment in Stryker Corporation $SYK

NBT Bank N.A. acquired a new stake in Stryker Corporation (NYSE:SYK) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 4,215 shares of the medical technology company’s stock, valued at approximately $1,161,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Bank of America Corp DE bought a new position in shares of Stryker in the second quarter valued at approximately $1,404,284,000. Legal & General Group Plc acquired a new stake in shares of Stryker in the second quarter worth $707,212,000. Jupiter Topco LLC acquired a new stake in shares of Stryker in the second quarter worth $681,581,000. Corient Private Wealth LP bought a new stake in shares of Stryker during the 2nd quarter worth $323,035,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Stryker during the 2nd quarter worth $464,506,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $307.65 on Friday. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The firm has a market capitalization of $118.01 billion, a PE ratio of 31.88, a PEG ratio of 1.98 and a beta of 0.78. The business’s 50 day moving average is $295.23 and its 200-day moving average is $311.93. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Analysts Set New Price Targets

SYK has been the topic of several recent analyst reports. Stifel Nicolaus dropped their target price on shares of Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Royal Bank Of Canada decreased their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Barclays raised Stryker to a “strong-buy” rating in a research report on Wednesday, October 7th. Argus set a $370.00 price objective on Stryker in a research note on Thursday, July 9th. Finally, Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $369.00.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.